PMID- 25854747
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 69
IP  - 7
DP  - 2015 Jul
TI  - Symptom report and treatment experience of hypogonadal men with and without type 
      2 diabetes in a United States health plan.
PG  - 783-90
LID - 10.1111/ijcp.12636 [doi]
AB  - BACKGROUND: Although hypogonadism (HG) is interrelated with type 2 diabetes 
      mellitus (T2DM), there is little information about men's experiences with HG, 
      T2DM, and testosterone replacement therapy (TRT). We examined symptoms and TRT 
      use among men with HG, with and without T2DM, who received care within a single 
      United States health plan. METHODS: Men aged >/= 18 years with HG, with and without 
      T2DM, were identified from the 2008 to 2010 Reliant Medical Group electronic 
      medical record database. Surveys responses compared by T2DM status using 
      chi-square or Wilcoxon rank sum tests. RESULTS: A total of 93 men were included 
      (19 with HG and T2DM, 74 with HG only). Men with both HG and T2DM were more 
      frequently treated for their HG by an endocrinologist (52.6%), compared with men 
      with HG only (28.4%, p = 0.058). Erectile dysfunction (ED) was the primary reason 
      for seeking care among all surveyed men, although men with HG and T2DM reported 
      experiencing ED more often (94.7%) than men with HG only (46.0%, p < 0.0001). 
      Additional reasons for seeking care were similar between cohorts and included 
      loss of energy and decreased sex drive. Most men (88.2%) reported using TRT, 
      primarily as injection or gel formulations. Discontinuation of TRT was reported 
      slightly more frequently by men with HG and T2DM (68.4%), compared with men with 
      HG only (55.4%, p > 0.05). CONCLUSIONS: This study provides information about 
      symptoms and TRT utilisation among HG men with and without T2DM. Men with HG only 
      were less likely than those with both HG and T2DM to report that they were 
      currently experiencing key symptoms compared with when they were first diagnosed, 
      regardless of TRT utilisation, and were less likely to report ED as a current 
      symptom.
CI  - (c) 2015 John Wiley & Sons Ltd.
FAU - Shortridge, E F
AU  - Shortridge EF
AD  - Spine and Biologics, Medtronic Inc., Memphis, TN, USA.
FAU - Polzer, P
AU  - Polzer P
AD  - Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA.
FAU - Donga, P
AU  - Donga P
AD  - Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA, USA.
FAU - Wade, R L
AU  - Wade RL
AD  - Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA, USA.
LA  - eng
PT  - Journal Article
DEP - 20150409
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Androgens)
RN  - 3XMK78S47O (Testosterone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Androgens/therapeutic use
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*complications/epidemiology
MH  - Erectile Dysfunction/drug therapy/epidemiology/*etiology
MH  - *Health Planning
MH  - Hormone Replacement Therapy/*methods
MH  - Humans
MH  - Hypogonadism/complications/drug therapy/*epidemiology
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Testosterone/*therapeutic use
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2015/04/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/04/10 06:00
PHST- 2015/04/10 06:00 [entrez]
PHST- 2015/04/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1111/ijcp.12636 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2015 Jul;69(7):783-90. doi: 10.1111/ijcp.12636. Epub 2015 Apr 
      9.